Brain tumor location influences the onset of acute psychiatric adverse events of levetiracetam therapy: an observational study
- PMID: 28315958
- DOI: 10.1007/s00415-017-8463-6
Brain tumor location influences the onset of acute psychiatric adverse events of levetiracetam therapy: an observational study
Abstract
To explore possible correlations among brain lesion location, development of psychiatric symptoms and the use of antiepileptic drugs (AEDs) in a population of patients with brain tumor and epilepsy. The medical records of 283 patients with various types of brain tumor (161 M/122 F, mean age 64.9 years) were analysed retrospectively. Patients with grade III and IV glioma, previous history of epileptic seizures and/or psychiatric disorders were excluded. Psychiatric symptoms occurring after initiation of AED therapy were considered as treatment emergent psychiatric adverse events (TE-PAEs) if they fulfilled the following conditions: (1) onset within 4 weeks after the beginning of AED therapy; (2) disappearance on drug discontinuation; (3) absence of any other identified possible concurrent cause. The possible influence of the following variables were analysed: (a) AED drug and dose; (b) location and neuroradiologic features of the tumor, (c) location and type of EEG epileptic abnormalities, (d) tumor excision already or not yet performed; (e) initiation or not of radiotherapy. TE-PAEs occurred in 27 of the 175 AED-treated patients (15.4%). Multivariate analysis showed a significant association of TE-PAEs occurrence with location of the tumor in the frontal lobe (Odds ratio: 5.56; 95% confidence interval 1.95-15.82; p value: 0.005) and treatment with levetiracetam (Odds ratio: 3.61; 95% confidence interval 1.48-8.2; p value: 0.001). Drug-unrelated acute psychiatric symptoms were observed in 4 of the 108 AED-untreated patients (3.7%) and in 7 of the 175 AED-treated patients (4%). The results of the present study suggest that an AED alternative to levetiracetam should be chosen to treat epileptic seizures in patients with a brain tumor located in the frontal lobe to minimize the possible onset of TE-PAEs.
Keywords: Epilepsy; Levetiracetam; Psychiatric adverse events; Tumor frontal lobe location.
Similar articles
-
Are psychiatric adverse events of antiepileptic drugs a unique entity? A study on topiramate and levetiracetam.Epilepsia. 2007 Dec;48(12):2322-6. doi: 10.1111/j.1528-1167.2007.01262.x. Epub 2007 Aug 17. Epilepsia. 2007. PMID: 17711462
-
Psychiatric side effects and antiepileptic drugs: Observations from prospective audits.Epilepsy Behav. 2017 Jun;71(Pt A):73-78. doi: 10.1016/j.yebeh.2017.04.003. Epub 2017 May 25. Epilepsy Behav. 2017. PMID: 28551500
-
Neuropsychiatric adverse events of antiepileptic drugs in brain tumour-related epilepsy: an Italian multicentre prospective observational study.Eur J Neurol. 2017 Oct;24(10):1283-1289. doi: 10.1111/ene.13375. Epub 2017 Aug 10. Eur J Neurol. 2017. PMID: 28796376
-
Levetiracetam for managing neurologic and psychiatric disorders.Am J Health Syst Pharm. 2009 Mar 15;66(6):541-61. doi: 10.2146/ajhp070607. Am J Health Syst Pharm. 2009. PMID: 19265183 Review.
-
Psychiatric effects of antiepileptic drugs in adults.Geriatr Psychol Neuropsychiatr Vieil. 2018 Jun 1;16(2):181-188. doi: 10.1684/pnv.2018.0733. Geriatr Psychol Neuropsychiatr Vieil. 2018. PMID: 29877186 Review. English.
Cited by
-
Brain tumor related epilepsy: pathophysiological approaches and rational management of antiseizure medication.Neurol Res Pract. 2022 Sep 5;4(1):45. doi: 10.1186/s42466-022-00205-9. Neurol Res Pract. 2022. PMID: 36059029 Free PMC article. Review.
-
Associations of levetiracetam use with the safety and tolerability profile of chemoradiotherapy for patients with newly diagnosed glioblastoma.Neurooncol Adv. 2022 Jul 7;4(1):vdac112. doi: 10.1093/noajnl/vdac112. eCollection 2022 Jan-Dec. Neurooncol Adv. 2022. PMID: 35950086 Free PMC article.
-
Antiepileptic and psychiatric medication in a nationwide cohort of patients with glioma WHO grade II-IV.J Neurooncol. 2018 Dec;140(3):739-748. doi: 10.1007/s11060-018-03007-9. Epub 2018 Nov 23. J Neurooncol. 2018. PMID: 30471051
-
HLA-A*11:01 is associated with levetiracetam-induced psychiatric adverse events.PLoS One. 2018 Jul 18;13(7):e0200812. doi: 10.1371/journal.pone.0200812. eCollection 2018. PLoS One. 2018. PMID: 30020991 Free PMC article.
-
The efficacy and safety of novel antiepileptic drugs in treatment of epilepsy of patients with brain tumors.Front Neurol. 2024 Mar 7;15:1344775. doi: 10.3389/fneur.2024.1344775. eCollection 2024. Front Neurol. 2024. PMID: 38523608 Free PMC article. Review.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical